https://orcid.org/0000-0002-4305-7766
-
Views
-
Cite
Cite
Lu Hao, Jisu Xue, Letter to the Editor From Hao and Xue: “Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-Peptide Loss and Pancreatic Atrophy”, The Journal of Clinical Endocrinology & Metabolism, Volume 110, Issue 2, February 2025, Pages e550–e551, https://doi.org/10.1210/clinem/dgae554
Close - Share Icon Share
Extract
The study by Wu et al (1) provides informative and substantial work in the field of oncoimmunology and endocrinology, where the focus lies with the rapid C-peptide loss, reduction in pancreatic volume, and importance placed on the same for the diagnostic criteria of checkpoint inhibitor–associated autoimmune diabetes mellitus (CIADM) in their patients. However, a few issues are still open for discussion.
First, the original study does not evaluate the specific effects of different immune checkpoint inhibitors (ICIs), which would potentially result in various degrees of increased CIADM risks, especially the differential risk profiles between PD-1 and PD-L1 inhibitors (2). We recommend the authors plan analyses separately from the beginning of the study design for exploring different classes of ICIs. This may help to differentiate which class of ICIs would be contributing toward higher or lower increased risks of CIADM. It helps clinicians make more informed decisions when selecting ICIs and reduces the incidence of CIADM.
